INSM — Insmed Incorporated

Is INSM overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of October 3, 2026

Insmed Incorporated (INSM) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $111.12. The rating moved from Neutral to Oversold on September 25, 2026.

See all oversold Healthcare stocks →

AI analysis

Insmed Incorporated (INSM) combines an established commercial product base with late-stage biologic assets that create near-term catalysts and optionality. The company’s financial position and recent capital activity support ongoing development programs, while investor appetite for specialty biotech can underpin valuation if clinical readouts are favorable. However, exposure to payer reforms and Medicare negotiation introduces pricing pressure risk, and biotech-specific clinical/regulatory setbacks would materially impact the outlook. Near-term performance will be sensitive to macro risk sentiment, upcoming data/approval milestones, and execution on commercialization and manufacturing.

Key factors

  • Late-stage biologics investor appetite supports financing and M&A optionality for specialty biotech assets
  • Commercial product franchise providing recurring revenue and a measurable path to profitability (established market presence for lead product)
  • Favorable balance sheet cadence vs peers with recent capital events and cash runway sufficient for near-term development milestones
  • Upcoming clinical/readout and regulatory catalysts that could meaningfully re-rate valuation if positive
  • Market risk-off and sector rotation into defensive assets may reduce near-term upside volatility but can also mute share moves
  • Policy and payer pressure (Medicare negotiation / IRA) could compress pricing for high-cost therapies, but company focus on niche indications may partially insulate volume

Risks

  • Clinical development risk: negative trial results or delayed readouts for late-stage assets
  • Regulatory risk: FDA approval delays, additional data requests, or label restrictions
  • Pricing and reimbursement pressure from Medicare negotiation / PBM dynamics reducing net price realization
  • Competitive risk from larger biopharma entrants or new therapeutic classes impacting market share
  • Manufacturing and supply-chain disruptions affecting product availability or cost of goods
  • Market volatility and liquidity risk in biotech shares, exacerbated by risk-off macro sentiment
  • Execution risk around commercialization scale-up and international launch strategies

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for INSM — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.